



INDIA GLYCOLS LIMITED

Plot No. 2-B, Sector - 126, NOIDA-201304, Distt. Gautam Budh Nagar (Uttar Pradesh), Tel. : +91 (120) 6860000, 3090100, 3090200
Fax : +91 (120) 3090111, 3090211, E-mail : iglho@indiaglycols.com, Website : www.indiaglycols.com

IGL/SE/2026-27/53

2nd September, 2026

The Manager (Listing)
BSE Limited
1st Floor, New Trading Ring,
Rotunda Building, P.J. Towers,
Dalal Street,
Mumbai – 400 001

The Manager (Listing)
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (East),
Mumbai- 400 051

Scrip Code: 500201

Symbol: INDIAGLYCO

Dear Sirs,

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Investor Presentation for Analyst / Institutional Investor Meeting.

Further to our letter bearing no. IGL/SE/2026-27/50 dated 28th August, 2026 and pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, kindly find enclosed herewith investor presentation for the analyst / institutional investor meeting to be held on 2nd September, 2026.

This same is also being hosted on the Company's website at www.indiaglycols.com.

This is for your information and record.

Thanking you,

Yours truly,
For India Glycols Limited

Ankur Jain
Head (Legal) & Company Secretary
Encl: A/a

ENNATURE

BIOPHARMA





Ennature Biopharma

Investor presentation

September 2026

Strictly private and confidential


Structural Megatrends Accelerating Nutraceutical Demand



Source: Industry Research, WHO, ICMR, CRN Consumer Survey, LocalCircles Survey.
Note: (1) Non-Communicable Diseases. (2) BMI > 30. (3) BMI > 25. (4) Includes herbs vitamins, minerals, fibre and omega.


Scaled Botanical Opportunity, Increasingly Driven by Condition-Led Nutrition

Botanicals represent a scaled, established segment within the global supplement opportunity



Operating within a large botanical ingredients market, Ennature has built differentiated products around established ingredients

Consumers are moving from generic products toward targeted solutions addressing specific health outcomes



Ennature's science-backed botanical portfolio addresses high-priority health needs across condition-led categories

Ennature's Journey of Value Creation



Building on deep phyto-chemical expertise, Ennature is well positioned to take advantage of the huge opportunity in natural health & wellness space.

Three Businesses, One Natural Ingredients Platform

Mature core API business generates durable, predictable cash flows, fueling the strategic expansion into high-growth Branded Nutraceutical segment.

1

Plant based APIs



Products: Thiocolchicoside, Colchicine, Nicotine, Vinpocetine

Core business, Stable margins and moderate growth

67% of Sales

Mature, Cash Generative Business

2

Biopolymers



Products: Guar Gum and Speciality Gums

Core business, Growing segment

16% of Sales

Steady Business with Multiple Growth Prospects

3

Nutraceuticals



Products: Branded Ingredients, Standard Botanical Extracts, CDMO

Relatively New and Growing segment, High margins

17% of Sales

Future Growth Engine Fueled by the Core Portfolio

Shared expertise across Plant-based APIs, Biopolymers and Nutraceuticals creates a balanced portfolio of resilience, margins and growth

1

Established API Franchise Providing a Stable Foundation for Growth



Leadership in key APIs led by strong technology platform and quality systems, serving global and domestic pharmaceutical customers



Built over the past 15 years, the segment delivers high-value, niche and complex molecules while supporting new growth initiatives

Key Strategies

- 1 Scale Nicotine portfolio** – Shift towards long-term, higher-value pharmaceutical customers
- 2 Add 1 new API product a year** – Targeting niche, complex molecules
- 3 Deepen Regulated market penetration** – Broader access to the US, Europe and other regulated markets

Key Product Portfolio



Thiocolchicoside

Muscle Relaxant / Analgesic



Colchicine

Anti-inflammatory / Gout



Nicotine

Nicotine Replacement



Vinpocetine

Cognitive Health

CEP

2 Approved
2 Under-evaluation

US-DMF

2 Products

EU-GMP

26+

Countries

150+

Active
Customers

54%

Export
Revenues

Diversified Biopolymer (Guar) Platform Positioned for Sustainable Growth



Broad end-market exposure provides a resilient foundation, while dietary fibre and value-added derivatives drive the next phase of growth

Key Strategies

- 1 Scale Dietary Fibre Applications** – Expand participation in food, nutrition and health-focused applications
- 2 Grow Value-Added Derivatives** – Increase the contribution of specialized, application-led solutions
- 3 Deepen End-Market Penetration** – Grow customer relationships across

Key End Markets




Oil & Gas



F&B



Personal Care



Paints



Textiles



Supplements

Serving all end-markets

23+
Countries

23+
Active Customers

69%
Export Revenues

3

Scaling Branded Nutraceutical Ingredients as the Next Growth Engine



Expanding beyond standardized botanical extracts into higher-value, clinically validated branded ingredients with stronger customer stickiness

Key Strategies

- 1 Strengthen branded portfolio** – Deepening expertise across science, clinicals, regulatory and supply chain
- 2 Build US presence** – Local office established for customer coverage and stocking capabilities
- 3 Expand regulated market access** – Korea, Europe and Taiwan

Key Branded Product Portfolio



Aspargize™

- Fast-acting Shatavari
- Targeted for Menopause

Women's Health



Gingeren™

- Sustained release granules
- Targeted for Dysmenorrhea

Women's Health



Maxicura®

- High bioavailability at low dose

Bone & Joint Health



Xanthogreen®

- Fast-acting lutein esters

Eye Health



Berbisol™

- Bio-enhanced berberine
- Clinical trials underway

Metabolic Health

USFDA

NSF GMP

5

Flagship Branded ingredients

2

Branded Ingredients Planned

19+

Countries

90+

Active Customers

83%

Export Revenues

Well Positioned to Capture the Shift Towards High Value Nutraceutical Ingredients



Building a differentiated competitive **MOAT**

- **Expertise in working with** plant based phyto-actives
- **Investment in science** – Clinical studies, patented tech platforms and product patents
- **Pharma expertise** – Technology, Fully integrated manufacturing from R&D to semi-formulation and Quality Systems
- **Globally certified quality systems** – EU-GMP and US-FDA certified, built for the world's most regulated markets
- **Access to India's centuries old Ayurveda legacy** provides an edge in ingredient discovery, validation and formulation



ENNATURE BIOPHARMA

Nutraceuticals Outlook:

Establishing branded nutraceuticals as a differentiated, high-margin growth platform with 2-3 additional products in the pipeline

Creating Defensibility Through Intellectual Property and Clinical Evidence

Innovation and clinical validation transform botanical ingredients into differentiated, globally scalable brands

Patented Technology Platforms

LIMAN™
For Higher Solubility

SCEMOD™
For Higher Bioabsorption

Patented delivery technologies address key formulation challenges, creating differentiated ingredients with enhanced end-user benefits

Patents

9
Patents Filed

4
Under review patents

5
Granted patents

2
US patents

IP-led innovation enables Ennature to develop differentiated ingredients with stronger commercial relevance

Clinical Trials

20
Total clinical trials

3
Pre-Clinical

2
Publications

10
Aspargize™

5
Maxicama™

2
Gingeren™

Growing body of clinical evidence validates efficacy and supports the commercialization of science-backed ingredients

Specialized Manufacturing Built on Global Quality Standards

A technology-led manufacturing platform enabling product innovation, regulatory compliance and commercial scale-up

1

Best-in-Class Processing Infrastructure
 **India's largest SCFE¹ facility** with multi-process capabilities

2

Pharmaceutical-Grade Quality Systems
Globally benchmarked, audit-ready quality systems 

3

Scalable Technology Platform
 **Proprietary platforms** enabling differentiated product development

4

Superior Process Capabilities
End-to-end capabilities from development to scale-up 

Innovation

•

Quality

•

Scale



Dehradun

1,600 MT

Manufacturing Capacity

EU-GMP / CEP

21 CFR Part 11

FSSAI

ISO 9001:2015

ISO 22000:2018

USFDA

NSF-GMP

GRAS

Kashipur

24,000 MT

Manufacturing Capacity

Halal

OHSAS

Kosher

FSSAI

Note: (1) SCFE = Supercritical Fluid Extraction.

**Leveraging a stable core business to
accelerate future growth driven by
investments in high-value Nutraceutical
ingredients**

INR 246 Cr
Revenue

40.1%
Gross Margin

INR 29 Cr
EBITDA

11.9%
EBITDA
Margin

Business Outlook



API



Product portfolio expansion by launching one new API annually



Gain share in Nicotine and Thiocolchicoside



Expansion into **new geographies**



Establish NRT presence in pharma segment



Biopolymer (Guar)



Shift towards **higher-value product mix**



Expand into the emerging **dietary-fibre and food-ingredient** market



Develop **application-specific derivatives**



Broaden the customer base across geographies



Nutraceuticals



Primary growth driver for the company



Expand **clinical validation & scientific substantiation**



Scale to 6-8 branded ingredients




Expand distribution across the US, Europe and Asia



Deepen penetration with leading nutraceutical customers

Three pillars, one growth agenda — building a resilient, innovation-led health & wellness platform



ENNATURE

BIOPHARMA

Translating Nature's
Benefits with Science